DOCSLIB.ORG

Factors Influencing Opioid Receptor Signaling To

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Factors Influencing Opioid Receptor Signaling To FACTORS INFLUENCING OPIOID RECEPTOR SIGNALING TO ADENYLYL CYCLASE by Erica Sawyer Levitt A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Pharmacology) in The University of Michigan 2010 Doctoral Committee: Professor John R. Traynor, Chair Professor Henry I. Mosberg Associate Professor Jeffrey R. Martens Associate Professor Roger K. Sunahara © Erica Sawyer Levitt 2010 To my husband Trevor and my mother Barbara In memory of my father Steve ii Acknowledgements Firstly, I would like to thank my mentor Dr. John Traynor for taking the time to teach me the skills required to become a successful scientist. I appreciate his patience and guidance in learning how to think critically, prepare manuscripts, write grants and deliver presentations. I am very grateful for the true interest he has taken in preparing me for the next steps of my career. Overall, I thank him for providing a challenging and rewarding graduate school experience. I would like to thank Dr. Jeffrey Martens for providing guidance scientifically as a collaborator and thesis committee member, as well as for the special effort he has taken to help me in my career. I would also like to acknowledge Dr. Henry Mosberg and Dr. Roger Sunahara for their helpful advice and guidance. To the members of the Traynor lab, present and former, thank you for assistance scientifically and for creating a collaborative work environment. Specifically, I would like to thank Kelly Bosse, Faye Bradbury, Mary Clark, Alexander Delgado, Emily Jutkiewicz, Lauren Purington, Jennifer Thomson and Qin Wang. I would like to thank the undergraduates that have contributed to the work in this thesis, Alexander Harris, Tony McClafferty, Christine Zelnik and Jason Chen. Special thanks to those in the department who have provided assistance during my graduate career: the Jeffery Martens laboratory, especially Paul Jenkins for help with confocal imaging, lipid raft techniques and reagents; the Paul Hollenberg lab, especially Natasha Snider for providing cannabinoid ligands and advice; the Richard Neubig laboratory, including Sue Wade and Levi Blazer for providing adrenergic ligands and iii advice; the Department of Pharmacology administrative staff, especially Eileen Ferguson and Anna Taylor. I would like to recognize support and training received from the Pharmacological Sciences Training Program and the University of Michigan Substance Abuse Research Center Training Grant. I also acknowledge funding from the National Institutes of Health National Institute of Drug Abuse including a Ruth Kirschstein pre-doctoral NRSA. Finally, I would like to thank those outside of science who have supported me. My husband Trevor has been wonderful and I cannot thank him enough for the continuous encouragement and support he has provided. I would like to thank my mom for always believing in me and providing an environment that fostered my interest in learning. Last, but not least, I would like to thank my family and friends for keeping me balanced and helping me accomplish some of my other life goals, such as travel, staying active and keeping a light-hearted personality. I have made some great friends at Michigan, all of whom I am very grateful for and will miss very much. iv Table of Contents Dedication ........................................................................................................................... ii Acknowledgements ............................................................................................................ iii List of Figures ................................................................................................................... vii List of Tables ..................................................................................................................... ix List of Abbreviations .......................................................................................................... x Chapter I.............................................................................................................................. 1 General Introduction ........................................................................................................... 1 Opioid pharmacology...................................................................................................... 1 Opioid receptor signaling ................................................................................................ 4 Receptor coupling models............................................................................................... 6 Plasma membrane composition and organization........................................................... 9 Cholesterol and/or membrane microdomains in opioid receptor signaling .................. 15 Hypothesis and Aims .................................................................................................... 23 Chapter II .......................................................................................................................... 28 Differential effect of membrane cholesterol removal on MOR and DOR: A parallel comparison of acute and chronic signaling to adenylyl cyclase ....................................... 28 Summary ....................................................................................................................... 28 Introduction ................................................................................................................... 29 Materials and Methods .................................................................................................. 31 Results ........................................................................................................................... 36 v Discussion ..................................................................................................................... 47 Chapter III ......................................................................................................................... 63 Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid withdrawal-mediated cAMP overshoot ..................................................... 63 Summary ....................................................................................................................... 63 Introduction ................................................................................................................... 64 Materials and Methods .................................................................................................. 65 Results ........................................................................................................................... 69 Discussion ..................................................................................................................... 75 Chapter IV ......................................................................................................................... 91 Discussion and Future Directions ..................................................................................... 91 Future directions related to compartmentalization ....................................................... 92 Future directions related to cholesterol/membrane microdomains ............................... 94 Overall summary and significance .............................................................................. 100 References ....................................................................................................................... 104 vi List of Figures Figure 1.1: Schematic of opioid receptor signaling .......................................................... 27 Figure 2.1: MOR, but not DOR, agonist-mediated G protein activation is altered following MβCD treatment. .............................................................................................. 54 Figure 2.2: Cholesterol removal by MβCD induces low-affinity binding in MOR, but not DOR, expressing cells. ...................................................................................................... 55 Figure 2.3: MOR, but not DOR, agonist-mediated inhibition of adenylyl cyclase is altered following MβCD treatment. .................................................................................. 56 Figure 2.4: MβCD treatment blocks MOR, but not DOR, agonist-mediated adenylyl cyclase sensitization. ......................................................................................................... 57 Figure 2.5: Effects of MβCD on MOR signaling are due to removal of cholesterol from the membrane. ................................................................................................................... 58 Figure 2.6: Alterations in MOR signaling are not due to changes in receptor number. .. 59 Figure 2.7: Effect of cytoskeleton inhibitors on MOR-mediated adenylyl cyclase sensitization....................................................................................................................... 60 Figure 2.8: Localization of MOR, but not DOR, in caveolin-enriched fractions, in addition to transferrin receptor-enriched fractions. .......................................................... 61 Figure 2.9: DOR is not co-localized with cholera toxin B (CTB) subunit patches. ........ 62 Figure 3.1: Gi/o-coupled receptors endogenously expressed in SH-SY5Y cells share a common pool of AC.........................................................................................................
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun
    USOO9687445B2 (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun. 27, 2017 (54) ORAL FILM CONTAINING OPIATE (56) References Cited ENTERC-RELEASE BEADS U.S. PATENT DOCUMENTS (75) Inventor: Michael Hsin Chwen Li, Warren, NJ 7,871,645 B2 1/2011 Hall et al. (US) 2010/0285.130 A1* 11/2010 Sanghvi ........................ 424/484 2011 0033541 A1 2/2011 Myers et al. 2011/0195989 A1* 8, 2011 Rudnic et al. ................ 514,282 (73) Assignee: LTS Lohmann Therapie-Systeme AG, Andernach (DE) FOREIGN PATENT DOCUMENTS CN 101703,777 A 2, 2001 (*) Notice: Subject to any disclaimer, the term of this DE 10 2006 O27 796 A1 12/2007 patent is extended or adjusted under 35 WO WOOO,32255 A1 6, 2000 U.S.C. 154(b) by 338 days. WO WO O1/378O8 A1 5, 2001 WO WO 2007 144080 A2 12/2007 (21) Appl. No.: 13/445,716 (Continued) OTHER PUBLICATIONS (22) Filed: Apr. 12, 2012 Pharmaceutics, edited by Cui Fude, the fifth edition, People's Medical Publishing House, Feb. 29, 2004, pp. 156-157. (65) Prior Publication Data Primary Examiner — Bethany Barham US 2013/0273.162 A1 Oct. 17, 2013 Assistant Examiner — Barbara Frazier (74) Attorney, Agent, or Firm — ProPat, L.L.C. (51) Int. Cl. (57) ABSTRACT A6 IK 9/00 (2006.01) A control release and abuse-resistant opiate drug delivery A6 IK 47/38 (2006.01) oral wafer or edible oral film dosage to treat pain and A6 IK 47/32 (2006.01) substance abuse is provided.
    [Show full text]
  • Values of Several Opioid Receptor Agonists and Their Liability to Cause Depen- Dence
    Acta Pharmacologica Sinica (2010) 31: 393–398 npg © 2010 CPS and SIMM All rights reserved 1671-4083/10 $32.00 www.nature.com/aps Original Article Paradoxical relationship between RAVE (relative activity versus endocytosis) values of several opioid receptor agonists and their liability to cause depen- dence Yu-hua WANG1, 2, 3, Jian-feng SUN3, Yi-min TAO3, Xue-jun XU3, Zhi-qiang CHI3, Jing-gen LIU3, * 1School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China; 2School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210046, China; 3State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China Aim: To examine the relationship between the RAVE (relative activity versus endocytosis) values of opiate agonists and their dependence liability by studying several potent analgesics with special profiles in the development of physical and psychological dependence. Methods: The effects of (–)-cis-(3R,4S,2′R) ohmefentanyl (F9202), (+)-cis-(3R,4S,2′S) ohmefentanyl (F9204), dihydroetorphine (DHE) and morphine on [35S]GTPγS binding, forskolin-stimulated cAMP accumulation, and receptor internalization were studied in CHO cells stably expressing HA-tagged μ-opioid receptors (CHO-HA-MOR). cAMP overshoot in response to the withdrawal of these compound treatments was also tested. Results: All four agonists exhibited the same rank order of activity in stimulation of [35S]GTPγS binding, inhibition of adenylyl cyclase (AC) and induction of receptor internalization: DHE>F9204>F9202>morphine. Based on these findings and the previous in vivo analgesic data obtained from our and other laboratories, the RAVE values of the four agonists were calculated.
    [Show full text]
  • Tramadol and Dihydroetorphine Produce Synergistic Analgesic Effect and Postpones Acute Opiate Tolerance in Rats
    696 Acta Physiologica Sinica, December 25, 2005, 57 (6): 696-704 http://www.actaps.com.cn Research Paper Tramadol and dihydroetorphine produce synergistic analgesic effect and postpones acute opiate tolerance in rats MING Xiao-Yun1,2,**, WANG Wei1, **, HAN Ji-Sheng1, LUO Fei 1, * 1 Neuroscience Research Institute and Department of Neurobiology, School of Basic Medicine, Peking University, Beijing 100083, China; 2 Department of Physiology, Tai’an Medical College, Tai’an 271000, China Abstract: The present study investigated whether a co-application of tramadol (TRA) and dihydroetorphine (DHE) would exert a synergy in analgesic effect and delay acute tolerance development. Intraperitoneal injection of TRA (in mg) and subcutaneous injection of DHE (in ng) were delivered in fixed proportions (1:6.25, 1:12.5, 1:25, 1:50, 1:100, and 1:200). The effect of analgesia was accessed by tail-flick test and analyzed with isobolographic analysis. For test of acute tolerance, six successive injections of either TRA (20 mg/ kg) alone, DHE (1 000 ng/kg) alone, or a combination of TRA (20 mg/kg) and DHE (250 ng/kg) were administered. We found that (1) except for 1 mg: 6.25 ng and 1 mg: 50 ng, combinations, all the other ratios produced a significant synergy in their analgesic effect; (2) the effect of analgesia induced by repeated TRA plus DHE injections lasted significantly longer, indicating a slower onset of acute tolerance. These results indicate that TRA and DHE injections in certain dose ratios can induce synergistic analgesia, which is resistant against the development of acute tolerance.
    [Show full text]
  • Outline for Controlled Substances Program
    Environmental Health and Safety Controlled Substances Program Date of Issuance: Review Date: 10/1/2019 (no changes) 10/01/2018 Revision Number: Initial Prepared by: EH&S Table of Contents HEADINGS Introduction Applicability Responsibilities Registration Requirements Authorized Use Ordering/Purchasing Administering and Dispensing Inventory Procedures (Continuing Records) Security Disposal FORMS: Registering or renewing a DEA or state license (CMU) Controlled Substances Authorized users list (CMU) Employee questionnaire for those with access to controlled substances (CMU) Record of Form 222 use (Order form) (CMU) Records of Controlled Substance Purchases (CMU) Record of Controlled Substance Administering and dispensing (CMU) Controlled Substance Physical Inventory (CMU) DEA Registration of Persons doing research or analysis (Form 225) DEA Registration of Dispensers (Form 224) DEA Registration Instructional (Form 224 and 226 to renew) DEA Report of loss or theft (Form 106) DEA Report of drugs surrendered (From 41) DEA SCHEDULES: Schedule I Schedule II Schedule III Schedule IV Schedule V INTRODUCTION State and Federal regulations have been promulgated concerning the use and handling of US Department of Justice Drug Enforcement Administration (DEA) controlled substances. These regulations are in place to address materials which are or have the potential to be addictive or habit forming. These substances have been categorized into “schedules” that have been created by the DEA to reflect their level of concern. The “Carnegie Mellon University DEA Controlled Substances Program” is intended to ensure that Carnegie Mellon University is in compliance with our regulatory requirements. Required activities under the DEA include: 1. Registration of your work with the DEA and with Carnegie Mellon’s Department of Environmental Health and Safety (EH&S).
    [Show full text]
  • Supplement 1: Additional Tables and Figures
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Global Health Supplement 1: Additional tables and figures Box S1: Substances included and excluded from the International Narcotic Control Board (INCB) data on narcotic consumption, in alphabetical order. Opioids included in the opioid consumption calculation: 1. (+)-cis-3-methylfental 35. Bezitramide 2. 3-Acetylmorphine 36. Butyrfentanyl 3. 3-Methylfentanyl 37. Carfentanil 4. 3-Methylthiofentanyl 38. Carfentanyl 5. 3-Monoacetylmorphine 39. Clonitazene 6. 4-Fluoroisobutyrfentanyl 40. Codeine 7. 6-Acetylmorphine 41. Codeine-6GLUC 8. 6-Monoacetylmorphine 42. Codeine-6-glucuronide 9. Acetorphine 43. Codeine-Methyl 10. Acetyl-alpha-methylfentanyl 44. Codeine-N-oxide 11. Acetyldihydrocodeine 45. Codoxime 12. Acetylfentanyl 46. Conc. of poppy straw (C) ACA 13. Acetylmethadol 47. Conc. of poppy straw (C) AMA 14. Acetylmorphine 48. Conc. of poppy straw (C) AOA 15. Acrylfentanyl 49. Conc. of poppy straw (C) ATA 16. AH-7921 50. Conc. of poppy straw (C) GW 17. Alfentanil 51. Conc. of poppy straw (M) ACA 18. Allylprodine 52. Conc. of poppy straw (M) AMA 19. Alphacetylmethadol 53. Conc. of poppy straw (M) AOA 20. Alphameprodine 54. Conc. of poppy straw (M) ATA 21. Alphamethadol 55. Conc. of poppy straw (M) GW 22. alpha-Methylfentanyl 56. Conc. of poppy straw (N) GW 23. alpha-Methylthiofentanyl 57. Conc. of poppy straw (O) 24. Alphaprodine 58. Conc. of poppy straw (O) ACA 25. Anileridine 59. Conc. of poppy straw (O) AMA 26. Benzethidine 60. Conc. of poppy straw (O) AOA 27.
    [Show full text]
  • Effects of Medication-Assisted Treatment (MAT) on Functional Outcomes Among Patients with Opioid Use Disorder (OUD)
    NATIONAL DEFENSE RESEARCH INSTITUTE Effects of Medication- Assisted Treatment (MAT) for Opioid Use Disorder on Functional Outcomes A Systematic Review Margaret A. Maglione, Laura Raaen, Christine Chen, Gulrez Shah Azhar, Nima Shahidinia, Mimi Shen, Ervant J. Maksabedian Hernandez, Roberta M. Shanman, Susanne Hempel Prepared for the Office of the Secretary of Defense Approved for public release; distribution unlimited For more information on this publication, visit www.rand.org/t/RR2108 Published by the RAND Corporation, Santa Monica, Calif. © Copyright 2018 RAND Corporation R® is a registered trademark. Limited Print and Electronic Distribution Rights This document and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited. Permission is given to duplicate this document for personal use only, as long as it is unaltered and complete. Permission is required from RAND to reproduce, or reuse in another form, any of its research documents for commercial use. For information on reprint and linking permissions, please visit www.rand.org/pubs/permissions. The RAND Corporation is a research organization that develops solutions to public policy challenges to help make communities throughout the world safer and more secure, healthier and more prosperous. RAND is nonprofit, nonpartisan, and committed to the public interest. RAND’s publications do not necessarily reflect the opinions of its research clients and sponsors. Support RAND Make a tax-deductible charitable contribution at www.rand.org/giving/contribute www.rand.org Preface Over the past two decades, the U.S. Department of Defense (DoD) has invested unparalleled resources into developing effective treatments for military-related psychological health conditions.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,846,975 Pan Et Al
    USOO5846975A United States Patent (19) 11 Patent Number: 5,846,975 Pan et al. (45) Date of Patent: Dec. 8, 1998 54 USE OF AMINO HYDROGENATED FOREIGN PATENT DOCUMENTS QUINAZOLINE COMPOUNDS AND B41-010330 6/1966 Japan. DERVATIVES THEREOF FOR ABSTAINING B44-010903 6/1966 Japan. FROM DRUG DEPENDENCE B44-010904 6/1966 Japan. B44-010906 6/1966 Japan. 75 Inventors: Xinfu Pan, Beijing; Fanglong Qiu, B42-009355 5/1967 Japan. Hunan, both of China B42-009356 5/1967 Japan. 1370905 10/1974 United Kingdom. 73 Assignee: Nanning Maple Leaf Pharmaceutical Co., Ltd., Guangxi Province, China OTHER PUBLICATIONS 21 Appl. No.: 640,781 Y. Kishi et al., J. Am. Chem. Soc., 94:26, pp. 9217-9221 (Dec. 27, 1972). 22 PCT Filed: Mar. 11, 1995 T. Goto et al., Tetrahedron, vol. 21, pp. 2059–2088 (1965). E. Murtha et al., Journal of Pharmacology and Experimen 86 PCT No.: PCT/CN95/00016 tal Therapeutics., vol. 122, pp. 247-254 (1958). S371 Date: May 21, 1996 Chemical Abstracts AN 1977: 268, Fredrikson et al., 1976. S 102(e) Date: May 21, 1996 Primary Examiner Keith D. MacMillan Attorney, Agent, or Firm-Birch, Stewart, Kolasch & Birch, 87 PCT Pub. No.: WO95/24903 LLP PCT Pub. Date: Sep. 21, 1995 57 ABSTRACT 30 Foreign Application Priority Data This invention relates to the use of amino hydrogenated quinazoline compounds and derivatives thereof, Such as Mar. 17, 1994 ICN China ............................. 941 10873.2 tetrodotoxin, for abstaining from drug dependence in (51) Int. Cl." ................................................... A61K 31/505 human. Such compounds are administered by Subcutaneous, 52 U.S.
    [Show full text]
  • 19 CSR 30-1.042 Inventory Requirements
    Rules of Department of Health and Senior Services Division 30—Division of Regulation and Licensure Chapter 1—Controlled Substances Title Page 19 CSR 30-1.002 Schedules of Controlled Substances .........................................................3 19 CSR 30-1.004 List of Excepted Substances.................................................................13 19 CSR 30-1.006 List of Exempt Anabolic Steroid Products................................................13 19 CSR 30-1.008 List of Excluded Veterinary Anabolic Steroid Implant Products......................14 19 CSR 30-1.010 Schedules of Controlled Substances (Rescinded November 30, 2000)...............14 19 CSR 30-1.011 Definitions......................................................................................15 19 CSR 30-1.013 Miscellaneous Fees ...........................................................................16 19 CSR 30-1.015 Registrations and Fees........................................................................16 19 CSR 30-1.017 Registration Process ..........................................................................16 19 CSR 30-1.019 Registration Location.........................................................................19 19 CSR 30-1.020 List of Excepted Substances (Rescinded November 30, 2000)........................19 19 CSR 30-1.023 Registration Changes .........................................................................19 19 CSR 30-1.025 List of Exempt Anabolic Steroid Products (Rescinded November 30, 2000).......20 19 CSR 30-1.026
    [Show full text]
  • Federal Register/Vol. 85, No. 230/Monday, November 30, 2020
    76604 Federal Register / Vol. 85, No. 230 / Monday, November 30, 2020 / Notices notifications disclosing all changes in Act on September 18, 2020 (85 FR DEPARTMENT OF JUSTICE membership. 58390). Drug Enforcement Administration On September 10, 2018, CONFERS Suzanne Morris, [Docket No. DEA–688E] filed its original notification pursuant to Chief, Premerger and Division Statistics, Section 6(a) of the Act. The Department Antitrust Division. Established Aggregate Production of Justice published a notice in the [FR Doc. 2020–26362 Filed 11–27–20; 8:45 am] Federal Register pursuant to Section Quotas for Schedule I and II Controlled BILLING CODE P Substances and Assessment of 6(b) of the Act on October 19, 2018 (83 Annual Needs for the List I Chemicals FR 53106). Ephedrine, Pseudoephedrine, and The last notification was filed with DEPARTMENT OF JUSTICE Phenylpropanolamine for 2021 the Department on May 1, 2020. A notice was published in the Federal Antitrust Division AGENCY: Drug Enforcement Register pursuant to Section 6(b) of the Administration, Department of Justice. Act on May 28, 2020 (85 FR 32049). Notice Pursuant to the National ACTION: Final order. Cooperative Research and Production Suzanne Morris, Act of 1993—Cooperative Research SUMMARY: This final order establishes Chief, Premerger and Division Statistics, Group on AC2AT–II the initial 2021 aggregate production Antitrust Division. quotas for controlled substances in [FR Doc. 2020–26358 Filed 11–27–20; 8:45 am] Notice is hereby given that, on schedules I and II of the Controlled Substances Act and the assessment of BILLING CODE 4410–11–P November 19, 2020, pursuant to Section 6(a) of the National Cooperative annual needs for the list I chemicals Research and Production Act of 1993, ephedrine, pseudoephedrine, and DEPARTMENT OF JUSTICE 15 U.S.C.
    [Show full text]
  • Committee on Energy and Commerce U.S. House of Representatives Witness Disclosure Requirement - "Truth in Testimony" Required by House Rule XI, Clause 2(G)(5)
    Committee on Energy and Commerce U.S. House of Representatives Witness Disclosure Requirement - "Truth in Testimony" Required by House Rule XI, Clause 2(g)(5) 1. Your Name: Patrick M. Beardsley, Ph.D. 2. Your Title: Professor, Pharmacology and Toxicology 3. The Entity(ies) You are Representing: Self; selected by American Society for Pharmacology and Experimental Therapeutics 4. Are you testifying on behalf of the Federal, or a State or local Yes No government entity? x Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed. 1. Beardsley, P. M., (PI) (2017-2022). Preclinical medications discovery and abuse liability testing for the National Institute on Drug Abuse. $4,318,971. $7,607,514 (Ultimate Contract Value (Base Period, Option Periods, and Option Quantities), National Institute on Drug Abuse. 2. Beardsley, P. M. (PI) (2017). Analgesia studies: Solicitation number: D-17-OD-0092, Drug Enforcement Agency. $149,040. 3. Beardsley, P. M., (PI) (2014). Medication discovery using rat models of relapse. $2,954,759. $4,496,997 (Ultimate Contract Value (Base Period, Option Periods, and Option Quantities), National Institute on Drug Abuse. 1. Please attach your curriculum vitae to your completed disclosure form. Signature: _______________ ____Date:____20180228_____________ CURRICULUM VITAE PATRICK M. BEARDSLEY, Ph.D. Virginia Commonwealth University Department of Pharmacology & Toxicology, Institute for Drug and Alcohol Studies & Center for Biomarker Research and Personalized Medicine 410 N.
    [Show full text]
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2013 (January Update)
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2013 (January update) Afghanistan Oxycodone 43 000 Codeine 50 000 Oxymorphone 300 Dextropropoxyphene 2 000 000 Pethidine 65 000 Diphenoxylate 20 000 Remifentanil 9 100 Fentanyl 6 Sufentanil 1 Methadone 6 000 Thebaine 45 000 Morphine 4 000 Armenia Pethidine 80 000 Codeine 3 000 Pholcodine 100 000 Fentanyl 21 Albania Methadone 10 000 Codeine 35 000 Morphine 4 500 Fentanyl 40 Thebaine 10 Methadone 9 000 Trimeperidine 650 Morphine 3 000 Aruba* Pethidine 2 500 Alfentanil 3 Pholcodine 1 000 Bezitramide 1 Remifentanil 8 Cocaine 70 Sufentanil 1 Codeine 85 Algeria Dextromoramide 1 Alfentanil 500 Dextropropoxyphene 85 Codeine 1 000 000 Fentanyl 130 Etorphine 1 Hydrocodone 2 Fentanyl 1 000 Methadone 150 Morphine 11 000 Morphine 340 Pethidine 3 000 Opium 450 Pholcodine 2 500 000 Oxycodone 26 Sufentanil 30 Pethidine 404 Andorra Piritramide 20 Fentanyl 80 Remifentanil 19 Methadone 1 000 Ascension Island Morphine 500 Alfentanil 1 Oxycodone 1 500 Fentanyl 1 Pethidine 500 Morphine 2 Remifentanil 4 Pethidine 9 Angola* Australia Alfentanil 2 Alfentanil 400 Codeine 30 000 Cannabis 21 500 Dextromoramide 375 Cocaine 20 000 Dihydrocodeine 375 Codeine 9 800 000 Fentanyl 45 Conc. of poppy straw Morphine 11 000 AOA 4 000 000 Pethidine 13 000 ATA 85 000 000 Sufentanil 2 Dextromoramide 10 Anguilla Dextropropoxyphene 1 925 000 Fentanyl 1 Difenoxin 7 Morphine 20 Dihydrocodeine 285 000 Pethidine 300 Diphenoxylate 80 000 Antigua and Barbuda* Ethylmorphine 10 Cocaine 9 Etorphine 2 Codeine 169 Fentanyl 40 000
    [Show full text]
  • Federal Register/Vol. 85, No. 36/Monday, February 24
    Federal Register / Vol. 85, No. 36 / Monday, February 24, 2020 / Notices 10475 Drug Controlled substance code Schedule Pentobarbital ............................................................................................................................................................................ 2270 II Secobarbital ............................................................................................................................................................................. 2315 II Glutethimide ............................................................................................................................................................................. 2550 II Nabilone ................................................................................................................................................................................... 7379 II 1-Phenylcyclohexylamine ........................................................................................................................................................ 7460 II Phencyclidine ........................................................................................................................................................................... 7471 II 4-Anilino-N-phenethyl-4-piperidine (ANPP) ............................................................................................................................. 8333 II Phenylacetone ........................................................................................................................................................................
    [Show full text]